Viking Therapeutics has initiated testing of a weight loss drug that goes beyond GLP-1 mechanisms, aiming to improve efficacy beyond current treatments from Eli Lilly and Novo Nordisk.
Finnhub07/19, 03:05 AM
Your privacy choice
S7 Markets works without measurement. If you allow it, we count which screens are opened and which actions are taken, on our own domain and never anything you typed. You can change this in Settings at any time.
Read the privacy policyNews story
Finnhub07/19, 03:05 AM